Literature DB >> 29120253

Brain-Derived Neurotrophic Factor in Patients with Primary Open-Angle Glaucoma and Age-related Cataract.

Alexander A Shpak1, Alla B Guekht2, Tatiana A Druzhkova2, Ksenia I Kozlova1, Natalia V Gulyaeva3.   

Abstract

PURPOSE: To study brain-derived neurotrophic factor (BDNF) content in aqueous humor (AH), lacrimal fluid (LF), and blood serum (BS) in patients with age-related cataract and primary open-angle glaucoma (POAG).
METHODS: BDNF was studied in 57 patients with age-related cataract, 55 patients with POAG combined with cataract, and 29 healthy controls (one eye in each person). AH was sampled during cataract surgery.
RESULTS: The levels of BDNF in LF and BS did not differ in cataract patients and controls. The concentration of BDNF (pg/mL) in patients with POAG and cataract was lower than in cataract patients in AH (35.2 ± 14.2 vs. 54.6 ± 29.6, P < 0.001), LF (78.0 ± 25.1 vs. 116.2 ± 43.1, P < 0.001), and BS (19230 ± 5960 vs. 22440 ± 7580, P < 0.02), while the AH/LF ratio was similar (0.46 ± 0.18 vs. 0.48 ± 0.19). The AH level of BDNF declined in early POAG and relatively increased in the next stages of the disease, inversely correlating with visual field index (Pearson's correlation coefficient r = -0.404, P = 0.002) and average retinal nerve fiber layer thickness (r = -0.322, P = 0.018). BDNF contents in LF and BS were also the lowest in early POAG. BDNF in AH strongly correlated with its content in LF (r = 0.66, P < 0.000). A formula was suggested to calculate the AH concentration of BDNF basing on its content in LF.
CONCLUSIONS: BDNF contents are decreased in AH, LF, and BS of patients with POAG demonstrating a significant decrease in the early POAG and relative increase in the next stages of the disease. A strong correlation exists between BDNF contents in AH and LF.

Entities:  

Keywords:  Brain-derived neurotrophic factor; age-related cataract; aqueous humor; blood serum; lacrimal fluid; primary open-angle glaucoma

Mesh:

Substances:

Year:  2017        PMID: 29120253     DOI: 10.1080/02713683.2017.1396617

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  11 in total

Review 1.  Potential neuroprotective biomolecules in ophthalmology.

Authors:  Mehrdad Afarid; Fatemeh Sanie-Jahromi
Journal:  Int Ophthalmol       Date:  2020-11-12       Impact factor: 2.031

Review 2.  Monitoring Neurodegeneration in Glaucoma: Therapeutic Implications.

Authors:  Norimitsu Ban; Carla J Siegfried; Rajendra S Apte
Journal:  Trends Mol Med       Date:  2017-12-07       Impact factor: 11.951

3.  Molecular Biomarkers for Glaucoma.

Authors:  Gala Beykin; Jeffrey L Goldberg
Journal:  Curr Ophthalmol Rep       Date:  2019-07-23

4.  Glial cell line-derived neurotrophic factor (GDNF) in patients with primary open-angle glaucoma and age-related cataract.

Authors:  Alexander A Shpak; Alla B Guekht; Tatiana A Druzhkova; Anna A Troshina; Natalia V Gulyaeva
Journal:  Mol Vis       Date:  2022-05-15       Impact factor: 2.711

Review 5.  Brain-Derived Neurotrophic Factor-Mediated Neuroprotection in Glaucoma: A Review of Current State of the Art.

Authors:  Lidawani Lambuk; Mohd Aizuddin Mohd Lazaldin; Suhana Ahmad; Igor Iezhitsa; Renu Agarwal; Vuk Uskoković; Rohimah Mohamud
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

6.  Increased ciliary neurotrophic factor in blood serum and lacrimal fluid as a potential biomarkers of focal epilepsy.

Authors:  Alexander Shpak; Alla Guekht; Tatiana Druzhkova; Flora Rider; Anna Gudkova; Natalia Gulyaeva
Journal:  Neurol Sci       Date:  2021-05-24       Impact factor: 3.307

7.  Tyrosine triple mutated AAV2-BDNF gene therapy in an inner retinal injury model induced by intravitreal injection of N-methyl-D-aspartate (NMDA).

Authors:  Asaka Lee Shiozawa; Tsutomu Igarashi; Maika Kobayashi; Kenji Nakamoto; Shuhei Kameya; Shigeto Fujishita; Hiroshi Takahashi; Takashi Okada
Journal:  Mol Vis       Date:  2020-06-03       Impact factor: 2.367

Review 8.  Target-Derived Neurotrophic Factor Deprivation Puts Retinal Ganglion Cells on Death Row: Cold Hard Evidence and Caveats.

Authors:  Marie Claes; Lies De Groef; Lieve Moons
Journal:  Int J Mol Sci       Date:  2019-09-03       Impact factor: 5.923

Review 9.  A novel viewpoint in glaucoma therapeutics: enriched environment.

Authors:  María F González Fleitas; Damián Dorfman; Ruth E Rosenstein
Journal:  Neural Regen Res       Date:  2022-07       Impact factor: 5.135

Review 10.  Discovery and clinical translation of novel glaucoma biomarkers.

Authors:  Gala Beykin; Anthony M Norcia; Vivek J Srinivasan; Alfredo Dubra; Jeffrey L Goldberg
Journal:  Prog Retin Eye Res       Date:  2020-07-10       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.